Role and challenges of proteomics in pharma and biotech: Technical, scientific and commercial perspective

Expert Review of Proteomics

Volumn 3, Issue 2, 2006, Pages 179-195

  Qoronfleh, M Walid ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

2DE; Antibodies; Biomarker; Bioreagent; Mass spectrometry; Protein array; Proteomics; Translational medicine

Indexed keywords

BIOLOGICAL MARKER;

DRUG DEVELOPMENT; GENOMICS; MASS SPECTROMETRY; MEDICAL INSTRUMENTATION; MEDICAL RESEARCH; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; TOXICOLOGY;

ANIMALS; BIOLOGICAL MARKERS; BIOTECHNOLOGY; DRUG INDUSTRY; HUMANS; MASS SPECTROMETRY; PROTEINS; PROTEOMICS;

EID: 33745605179     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.3.2.179     Document Type: Review

References (55)

1. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001).
2. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 291(5507), 1304-1351 (2001).
3. Mattick JS. The human genome and the future of medicine. Med. J. Aust. 179(4), 212-216 (2003).
4. Wilkins MR, Sanchez, JC, Gooley, AA et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol. Genet. Eng. Rev. 13, 19-50 (1996).
5. Patterson SD, Aebersold RH. Proteomics: the first decade and beyond. Nature Genet. 33(Suppl.), 311-323 (2003). • Excellent historical account on the evolution of the proteomics field.
6. Bilello JA. The agony and ecstasy of "omic" technologies in drug development. Curr. Mol. Med. 5(1), 39-52 (2005).
7. Loo JA. The tools of proteomics. Adv. Protein Chem. 65, 25-56 (2003). • Description of the various technologies and tools in protein science used in proteomics.
8. Guerrera IC, Kleiner O. Application of mass spectrometry in proteomics. Biosci. Rep. 25(1/2), 71-93 (2005).
9. MacCoss MJ, Yates JR. Proteomics: analytical tools and techniques. Curr. Opin. Clin. Nutr. Metabol. Care 4(5), 369-375 (2001).
10. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 422(6928), 198-207 (2003). •• Fantastic review on the role of mass spectrometry (MS) in proteomics.
11. Dhingra V, Gupta M, Andacht T, Fu ZF. New frontiers in proteomics research: a perspective. Int. J. Pharm. 299(1-2), 1-18 (2005).
12. Issaq, HJ, Conrads TP, Janini GM, Veenstra TD. Methods for fractionation, separation and profiling of proteins and peptides. Electrophoresis 23(17), 3048-3061 (2002). •• Lucid discussion of the main methods for protein and peptide separation and fractionation.
13. Lee WC, Lee KH. Applications of affinity chromatography in proteomics. Anal. Biochem. 324(1), 1-10 (2004).
14. Hunt DF, Henderson RA, Shabanowitz J et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255(5049), 1261-1263 (1992).
15. Stoll D, Bachmann J, Templin MF, Joos TO. Microarray technology: an increasing variety of screening tools for proteomic research. Drug Discov. Today: Targets 3(1), 24-31 (2004). • Comprehensive review of protein array methods and applications to proteomics.
16. Wang S, Sim TB, Kim Y-S, Chang Y-T. Tools for target identification and validation. Curr. Opin. Chem. Biol. 8(4), 371-377 (2004).
17. Aebersold R. A mass spectrometric journey into protein and proteome research. J. Am. Soc. Mass Spectrom. 14, 685-695 (2003).
18. Krijgsveld J, Heck AJR. Quantitative proteomics by metabolic labeling with stable isotopes. Drug Discov. Today: Targets 3(2 Suppl.), S11-S15 (2004).
19. Sechi S, Oda Y. Quantitative proteomics using mass spectrometry. Drug Discov. Today 9(Suppl. 2), S41-S46 (2004). • General review of the quantitative proteomics methods using MS.
20. Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3(12), 1154-69 (2004). •• Seminal paper reporting the novel isobaric tag for relative and absolute quantification (iTRAQ™) method for multiplexed protein quantitation.
21. Figeys D. Proteomics in 2002: a year of technical development and wide-ranging applications. Anal. Chem. 75(12), 2891-905 (2003).
22. Jacobs JM, Adkins JN, Qian W-J et al. Utilizing human blood plasma for proteomic biomarker discovery. J. Proteome Res. 4(4), 1073-1085 (2005). •• Key review reporting the recent advances, strategies and challenges in plasma proteome characterization.
23. Cho S, Park SG, Lee DH, Park BC. Protein-protein interaction networks: from interaction to networks. J. Biochem. Mol. Biol. 37(1), 45-52 (2004).
24. Auerbach D, Fetchko M, Stagljar. Proteomic approaches for generating comprehensive protein interaction maps. Drug Discov. Today: Targets 2(3), 85-92 (2003).
25. Burnet S, Thibault P, Gagnon E et al. Organelle proteomics: looking at less to see more. Drug Discov. Today 9(2 Suppl.), S8-S18 (2004).
26. Yates JR III, Gilchrist A, Howell KE, Bergeron JJ. Proteomics of organelles and large cellular structures. Nature Rev. Mol. Cell. Biol. 6(9), 702-714 (2005). •• Review of the state-of-the-art proteomics techniques for the analysis of subcellular structures and discussion of the biological insights that have been derived from such studies.
27. Seo J, Lee KJ. Post-translational modifications and their biological functions: proteomic analysis and systematic approaches. J. Biochem. Mol. Biol. 37(1), 35-44 (2004).
28. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nature Biotechnol. 21(3), 255-61 (2003). •• General, well-structured review on post-translational modification mapping.
29. Righetti PG, Castagna A, Antonioli P, Boschetti E. Prefractionation techniques in proteome analysis: the mining tools of the third millennium. Electrophoresis 26(2), 297-319 (2005). • Discusses prefractionation protocols used in proteomics investigation in preparation for MS or 2D electrophoresis map analysis.
30. Stasyk T, Huber LA. Zooming in: fractionation strategies in proteomics. Proteomics 4(12), 3704-3716 (2004). • Summarizes and discusses recent strategies in proteomics approaches where different fractionation strategies were successfully applied.
31. Dreger M. Subcellular proteomics. Mass Spectrom Rev. 22(1), 27-56 (2003). • Extensive elucidation of subcelluar analytical tools and proteome analysis.
32. Gingras AC, Aebersold R, Raught B. Advances in protein complex analysis using mass spectrometry. J. Physiol. 563(Pt 1), 11-21 (2005).
33. Reinders J, Sickmann A. State-of-the-art in phosphoproteomics. Proteomics 5(16), 4052-4061 (2005). •• Emphasizes the most frequently used methods in isolation and detection of phosphoproteins and peptides by various MS techniques.
34. Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R. Glycomics: an integrated systems approach to structure-function relationships of glycans. Nature Methods 2(11), 817-824 (2005). •• Glycomics review focuses on the different technologies that enable a systems approach to study glycan structure-function relationships.
35. Hanash S. Disease proteomics. Nature 422(6928), 226-232 (2003).
36. Figeys D. Proteomics approaches in drug discovery. Anal. Chem. 74(15), 412A-419A (2002).
37. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nature Rev. Drug Discov. 1(9), 683-695 (2002). • Comprehensive review on clinical proteomics, which highlights several application and specific disease examples.
38. Humphery-Smith I, Dracup W. The search for validated biomarkers in the face of biosystems complexity. Drug Discovery World 49-56 (2005).
39. Baker M. In biomarkers we trust? Nature Biotechnol. 23(3), 297-304 (2005).
40. Mankoff SP, Brander C, Ferrone S, Marincola FM. Lost in translation: obstacles to translational medicine. J. Transl. Med. 2, 14-18 (2004).
41. Zerhouni EA. US biomedical research: basic, translational and clinical sciences. JAMA 294(11), 1352-1358 (2005).
42. Boguski MS, McIntosh MW. Biomedical informatics for proteomics. Nature 422(6928), 233-237 (2003).
43. Souchelnytskyi S. Bridging proteomics and systems biology: what are the roads to be traveled? Proteomics 5(16), 4123-4137 (2005).
44. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J. Proteome Res. 3(2), 179-196 (2004).
45. Domon B, Broder S. Implications of new proteomics strategies for biology and medicine. J. Proteome Res. 3(2), 253-260 (2004)
46. Reinders J, Lewandrowski U, Moebius J, Wagner Y, Sickmann A. Challenges in mass spectrometry-based proteomics. Proteomics 4(12), 3686-3703 (2004).
47. Zolg JW, Langen H. How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell. Proteomics 3(4), 345-354 (2004). • Practical explanation of issues confronting diagnostic biomarkers in industry.
48. Hochstrasser DF, Sanchez JC, Appel RD. Proteomics and its trends facing nature's complexity. Proteomics 2(7), 807-812 (2002).
49. Liggett W, Cazares L, Semmes OJ. A look at mass spectral measurement. Chance 16(4), 24 (2003).
50. Liggett WS, Barker PE, Semmes OJ, Cazares LH. Measurement reproducibility in the early stages of biomarker development. Dis. Markers 20(6), 295-307 (2004).
51. Calvo KR, Liotta LA, Petricoin EF. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci. Rep. 25(1/2), 107-125 (2005).
52. Chaurand P, Sanders ME, Jensen RA, Caprioli RM. Proteomics in diagnostic pathology profiling and imaging proteins directly in tissue sections. Am. J. Pathol. 165(4), 1057-1068 (2004). • Narrative of imaging MS technology and its complementarity with traditional histopathological analyses.
53. Wetmore BA, Merrick BA. Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol. Pathol. 32(6), 619-642 (2004).
54. Bandara LR, Kennedy S. Toxicoproteomics - a new preclinical tool. Drug Discov. Today 7(7), 411-418 (2002). • Provides an overview of proteomics studies in toxicology with explicit examples.
55. Qoronfleh MW. Proteomics: the next frontier - a biotech perspective. J. Biomed. Biotechnol. 2004(3), 121-123 (2004).